Instead, when Sl-IFN is administered after chemotherapy, tumor antigens released in the surrounding tissue become available for presentation by tissue resident phagocytes [39,40], which, upon IFN-I encounter, become licensed for CD8+T cross-priming [65] and subsequently recirculate via the lymphatic vessels to the blood stream. Here, CD8A is linked to neoplasm.